The British-Swedish pharma major certainly has a strong competitive edge for BTC treatment in the country
_256_384.png)
Data show 37% reduction in risk of disease progression or death in men with metastatic castration-resistant prostate cancer treated with TALZENNA plus XTANDI
Durvalumab in combination with chemotherapy is indicated for the treatment of patients with locally advanced or metastatic biliary tract cancer
Experts’ conclave to pave holistic approach to cancer management
Approval marks fifth indication for KEYTRUDA-based regimens in NSCLC and 34th indication for KEYTRUDA in the US
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
The goal is to bring oncology therapy closer to the communities by integrating all services such as chemotherapy and radiation centers
First PARP inhibitor and new hormonal agent combination approved for these patients in Europe
EZHARMIA is the fifth innovative oncology medicine to be launched in Japan by Daiichi Sankyo in the past three years
Positive opinions based on significant survival benefit
Subscribe To Our Newsletter & Stay Updated
